Group 1 - BluSky AI Inc. has acquired its first operational site in Central Utah, securing 9.3 megawatts (MW) of power for its flagship data center project [1][2] - The company entered into a definitive Acquisition and Power Assignment Agreement with Digital Asset Management, LLC, allowing it to utilize 9.3 MW of grid-interconnected power at a competitive rate [2][3] - In exchange for power rights, BluSky AI issued 20 million shares of restricted common stock to DAM, ensuring long-term energy stability for the data center project [3] Group 2 - BluSky AI executed a Ground Lease with Wild Mustang Ventures LLC for 51.6 acres of land in Central Utah, with an initial two-year term and an annual base rent of $90,000 [4] - The company now controls 9.3 MW of power capacity, positioning it to rapidly deploy its modular AI compute infrastructure [5] - The CEO of BluSky AI emphasized that securing long-term, low-cost power and strategic land is a foundational moment for scaling AI infrastructure sustainably [6] Group 3 - BluSky AI Inc. is headquartered in Salt Lake City, Utah, and focuses on delivering modular, rapidly deployable data center infrastructure designed for artificial intelligence [7] - The company aims to provide high-performance infrastructure to support machine learning workloads for various partners, from startups to enterprises [7]

Core Insights - International Money Express, Inc. (Intermex) has launched a redesigned Remittance-as-a-Service (RaaS) platform aimed at facilitating cross-border money transfers for businesses [1][2] - The platform allows companies to offer branded payment services in various markets, including Latin America and select regions in Southeast Asia, the EU, and Africa [3][4] Group 1: Platform Features - The RaaS platform provides a customizable system for businesses to create branded customer experiences across multiple channels, including WhatsApp and mobile apps [4] - It includes essential compliance measures such as licensing, know your customer (KYC), and anti-money laundering (AML) protocols [4] - The platform supports a wide range of payout options, including cash pickups, home deliveries, and direct bank deposits, leveraging one of the largest payout networks in Latin America [4] Group 2: Business Benefits - The platform aims to eliminate barriers for businesses looking to innovate and expand by providing a turnkey solution built on extensive industry experience [4] - Companies can access integrated payment services, merchant account management, chargeback support, and advanced anti-fraud tools [4] - Intermex offers 24/7 bilingual customer support, business insights, and ongoing strategic guidance to its partners [4][5] Group 3: Company Background - Founded in 1994, Intermex specializes in facilitating money transfers from various countries to over 60 destinations, utilizing proprietary technology [6] - The company operates through a network of retail agents and company-operated stores, with headquarters in Miami, Florida, and international offices in Mexico, Guatemala, the UK, and Spain [6]

Core Insights - Longeveron Inc. has received FDA approval for its IND application for laromestrocel, a stem cell therapy aimed at treating pediatric dilated cardiomyopathy (DCM) [2][4] - The approval allows the company to proceed directly to a Phase 2 pivotal registration clinical trial, anticipated to begin in the first half of 2026 [8] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with laromestrocel being its lead investigational product [6] - Laromestrocel is derived from mesenchymal stem cells (MSCs) and has multiple potential mechanisms of action, including anti-inflammatory and pro-vascular regenerative responses [3][6] Disease Context - DCM is the most common form of cardiomyopathy in children, with 50-60% of pediatric cardiomyopathy cases diagnosed as dilated [5] - Nearly 40% of children diagnosed with DCM may require a heart transplant or may die within two years of diagnosis, highlighting the urgent need for effective treatments [3][8] Clinical Development - The IND approval marks a significant milestone in pediatric cardiovascular treatment, as current therapies primarily manage symptoms rather than address underlying causes [4] - The development program for laromestrocel reinforces Longeveron's commitment to innovative stem cell therapies for rare diseases, particularly in the cardiovascular space [3][4] Market Potential - Pediatric cardiomyopathies affect at least 100,000 children globally, indicating a substantial market opportunity for effective treatment options [8] - The innovative approach of using stem cells to repair damaged heart tissue could represent a groundbreaking development in treating cardiovascular diseases in children [4]

Core Viewpoint - SEALSQ Corp has initiated the deployment of its GSMA-accredited eUICC technology, integrating Post-Quantum cryptographic security to enhance mobile and IoT communications against current and future cyber threats [1][2][3]. Group 1: Technology and Innovation - The eUICC technology enables mobile phones, IoT devices, and connected infrastructure to benefit from advanced security measures that protect against quantum computing threats [2][6]. - SEALSQ's solution includes a GSMA Root CI-accredited Root Certificate Authority based in Switzerland, ensuring digital sovereignty and maximum trust within the global mobile ecosystem [3]. - The technology supports secure identification and authentication of eSIMs and Subscription Management entities, facilitating a transition from physical SIM cards to dynamic, remotely provisioned profiles [3][4]. Group 2: Applications and Market Impact - In smart city applications, SEALSQ's eUICC ensures data integrity and resilience, allowing municipalities to deploy IoT solutions confidently [4]. - The technology provides secure connectivity for industrial IoT applications across various sectors, safeguarding critical data [4][9]. - SEALSQ has invested in WISeSat.Space, enabling Telcos to access a satellite constellation for secure IoT connectivity, extending services from Earth to space [5]. Group 3: Future-Proofing and Security - The Post-Quantum-ready eUICC technology offers robust encryption, protecting mobile communications and financial transactions from quantum threats [6][8]. - This deployment represents a significant opportunity for Telcos and enterprises to enhance security and enable new business models in the context of AI and quantum computing [7]. - SEALSQ is focused on developing Post-Quantum Semiconductors that provide protection for sensitive data across various applications, ensuring organizations remain secure against quantum threats [9].

The management board of Northern Horizon Capital AS submitted today, 8 July 2025, an application to Nasdaq Stockholm for the delisting of the SDRs. The application was submitted in connection with the planned delisting of SDRs from Nasdaq Stockholm (notice of termination https://view.news.eu.nasdaq.com/view?id=1354309&lang=en) in accordance with the resolution of the fund manager dated 13 February 2025. The last day of trading in the SDR on Nasdaq Stockholm is planned to be on 8 October 2025. For additional ...

ENCINO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the appointment of Ian Smith to its Board of Directors, effective July 1, 2025. Mr. Smith brings with him over three decades of global leadership experience in financial services, with a proven track record in automotive finance, digital transformation and strategic grow ...

Core Insights - Vicon Industries has secured a follow-on order exceeding $1.2 million for a major government security upgrade project, indicating strong public-sector adoption of its video surveillance solutions [1][2][3] - The project includes high-performance cameras, recording servers, and Valerus video management software licenses, enhancing security across multiple county facilities [2][3] - This order reflects continued customer confidence in Vicon's reliability and system performance, contributing positively to Vicon's fiscal 2025 results [2][4] Strategic Outlook - The order is part of a broader trend of repeat institutional orders, particularly in government and education sectors, showcasing Vicon's growing market presence [3][4] - Vicon is transitioning from a legacy camera business to a modern surveillance technology platform, focusing on modular design and AI-enhanced analytics [4][5] - The company is positioned for meaningful year-over-year growth in fiscal 2025 and beyond, supported by recent industry awards and an expanding pipeline of institutional projects [5]

TYSONS, Va., July 08, 2025 (GLOBE NEWSWIRE) -- TEGNA Inc. (NYSE: TGNA) will host a conference call to discuss its second quarter 2025 earnings results on Thursday, August 7, 2025, at 11 a.m. (ET). The conference call will be webcast through the company’s website, and is open to investors, the financial community, the media and other members of the public. To access the meeting by phone, please visit investors.TEGNA.com at least 10 minutes prior to the scheduled start time to access the links and register be ...

Core Insights - Cloudastructure's AI-driven security platform achieved a deterrence rate of over 98% for threatening activities from January to May 2025, effectively preventing incidents such as theft and trespassing before escalation [1][2][3] - The platform generated 3.28 million alerts in the first five months of 2025, with 929,019 alerts in May alone, and facilitated 13,129 live audio interventions [2][3] - The company operates in 23 U.S. states and is expanding its presence in high-need markets such as multifamily housing, commercial real estate, and construction [5][6] Company Performance - Cloudastructure's subscription-based model and proprietary AI provide a compelling alternative to traditional security solutions, especially as municipalities face shrinking police resources and rising costs for on-site security [4][6] - The company offers a scalable, end-to-end security platform that replaces outdated surveillance systems, achieving strong gross margins and recurring revenue [4][7] - The platform's proactive approach to security, which includes intelligent detection and real-time human intervention, represents a transformative shift in the industry [6][7] Market Context - The rise in property crime nationwide highlights the effectiveness of Cloudastructure's platform at a time when traditional security solutions are under pressure [2][3] - The company's technology enables clients to achieve up to a 75% lower Total Cost of Ownership compared to other systems, enhancing its value proposition [7]

Core Insights - NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment to establish a new investment and clinical platform in the MENA region [1][2] - The partnership aims to leverage the UAE's clinical trial infrastructure to advance NeOnc's late-stage drug candidates [3][7] Investment and Structure - The term sheet outlines the formation of NuroMENA Holdings Ltd, which will oversee the establishment of NuroCure, an Abu Dhabi-based subsidiary responsible for clinical trials [2][5] - A proposed equity investment of $50 million is contingent upon NeOnc meeting specific conditions within 120 days [4][8] Clinical Development - NuroCure will initiate clinical trials for NEO100 and NEO212, targeting aggressive brain cancers such as Diffuse Intrinsic Pontine Glioma and glioblastoma multiforme [7][9] - The partnership is positioned to enhance NeOnc's clinical programs through collaboration with Cleveland Clinic Abu Dhabi [3][10] Financial Strategy - Quazar will lead a capital formation round of up to $50 million, with 70% allocated for acquiring NeOnc common stock and 30% for clinical trial and infrastructure development [8][10] - The investment strategy includes executing a Sub-License Agreement for NEO100 and NEO212, facilitating clinical efforts in the region [5][11] Company Background - NeOnc Technologies is focused on developing therapeutics for central nervous system cancers, with a robust patent portfolio extending to 2038 [11] - The company's drug candidates, NEO100 and NEO212, are currently in Phase II clinical trials under FDA Fast-Track status [11]